Found 11 bookmarks
Newest
Long COVID appears to be driven by ‘long infection’. Here’s what the science says
Long COVID appears to be driven by ‘long infection’. Here’s what the science says
“…in a perspective article published in the latest Medical Journal of Australia, we argue that much, if not all, long COVID appears to be driven by the virus itself persisting in the body.”
in a perspective article published in the latest Medical Journal of Australia, we argue that much, if not all, long COVID appears to be driven by the virus itself persisting in the body.
·theconversation.com·
Long COVID appears to be driven by ‘long infection’. Here’s what the science says
Fantastic review on chronic SARS-CoV-2 infections by virological superstars Richard Neher & Alex Sigal in Nature Microbiology. I’ll do a short overview, outline a couple minor quibbles, & defend the honor of ORF9b w/some stats & 3 striking sequences from the past week.
Fantastic review on chronic SARS-CoV-2 infections by virological superstars Richard Neher & Alex Sigal in Nature Microbiology. I’ll do a short overview, outline a couple minor quibbles, & defend the honor of ORF9b w/some stats & 3 striking sequences from the past week.
“Fantastic review on chronic SARS-CoV-2 infections by virological superstars Richard Neher & Alex Sigal in Nature Microbiology. I’ll do a short overview, outline a couple minor quibbles, & defend the honor of ORF9b w/some stats & 3 striking sequences from the past week.”
·x.com·
Fantastic review on chronic SARS-CoV-2 infections by virological superstars Richard Neher & Alex Sigal in Nature Microbiology. I’ll do a short overview, outline a couple minor quibbles, & defend the honor of ORF9b w/some stats & 3 striking sequences from the past week.
If there is a viral reservoir of SARS-CoV-2 why did the Stanford Paxlovid trial fail? The drug might be insufficient, or poor penetration in some reservoirs, or inappropriate end points, etc. Dominique Salmon MD PhD
If there is a viral reservoir of SARS-CoV-2 why did the Stanford Paxlovid trial fail? The drug might be insufficient, or poor penetration in some reservoirs, or inappropriate end points, etc. Dominique Salmon MD PhD
“If there is a viral reservoir of SARS-CoV-2 why did the Stanford Paxlovid trial fail? The drug might be insufficient, or poor penetration in some reservoirs, or inappropriate end points, etc. Dominique Salmon MD PhD”
·x.com·
If there is a viral reservoir of SARS-CoV-2 why did the Stanford Paxlovid trial fail? The drug might be insufficient, or poor penetration in some reservoirs, or inappropriate end points, etc. Dominique Salmon MD PhD
Towards a cure for long COVID: the strengthening case for persistently replicating SARS‐CoV‐2 as a driver of post‐acute sequelae of COVID‐19
Towards a cure for long COVID: the strengthening case for persistently replicating SARS‐CoV‐2 as a driver of post‐acute sequelae of COVID‐19
“the strengthening case for persistently replicating SARS-CoV-2 as a driver of post-acute sequelae of COVID-19”
the strengthening case for persistently replicating SARS-CoV-2 as a driver of post-acute sequelae of COVID-19
·onlinelibrary.wiley.com·
Towards a cure for long COVID: the strengthening case for persistently replicating SARS‐CoV‐2 as a driver of post‐acute sequelae of COVID‐19
Viral afterlife: SARS-CoV-2 as a reservoir of immunomimetic peptides that reassemble into proinflammatory supramolecular complexes | PNAS
Viral afterlife: SARS-CoV-2 as a reservoir of immunomimetic peptides that reassemble into proinflammatory supramolecular complexes | PNAS

SARS-CoV-2 peptide fragments can reassemble with dsRNA into proinflammatory complexes, amplifying immune responses.

These complexes trigger cytokine secretion in various cell types, mimicking severe COVID-19 inflammation.

·pnas.org·
Viral afterlife: SARS-CoV-2 as a reservoir of immunomimetic peptides that reassemble into proinflammatory supramolecular complexes | PNAS
Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study
Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study
“The findings of this multicohort study indicate that SARS-CoV-2 antigens can be detected in the blood of a substantial proportion of individuals up to 14 months after infection. While approximately one in five asymptomatic individuals was antigen-positive, roughly half of all individuals reporting ongoing cardiopulmonary, musculoskeletal, and neurologic symptoms were antigen-positive.”
The findings of this multicohort study indicate that SARS-CoV-2 antigens can be detected in the blood of a substantial proportion of individuals up to 14 months after infection. While approximately one in five asymptomatic individuals was antigen-positive, roughly half of all individuals reporting ongoing cardiopulmonary, musculoskeletal, and neurologic symptoms were antigen-positive.
·clinicalmicrobiologyandinfection.com·
Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study